Mark Steven Miller, Peter J Allen, Powel H Brown, Andrew T Chan, Margie L Clapper, Roderick H Dashwood, Shadmehr Demehri, Mary L Disis, Raymond N DuBois, Robert J Glynn, Thomas W Kensler, Seema A Khan, Bryon D Johnson, Karen T Liby, Steven M Lipkin, Susan R Mallery, Emmanuelle J Meuillet, Richard B S Roden, Robert E Schoen, Zelton D Sharp, Haval Shirwan, Jill M Siegfried, Chinthalapally V Rao, Ming You, Eduardo Vilar, Eva Szabo, Altaf Mohammed
{"title":"会议报告：癌症预防制剂开发转化进展会议。","authors":"Mark Steven Miller, Peter J Allen, Powel H Brown, Andrew T Chan, Margie L Clapper, Roderick H Dashwood, Shadmehr Demehri, Mary L Disis, Raymond N DuBois, Robert J Glynn, Thomas W Kensler, Seema A Khan, Bryon D Johnson, Karen T Liby, Steven M Lipkin, Susan R Mallery, Emmanuelle J Meuillet, Richard B S Roden, Robert E Schoen, Zelton D Sharp, Haval Shirwan, Jill M Siegfried, Chinthalapally V Rao, Ming You, Eduardo Vilar, Eva Szabo, Altaf Mohammed","doi":"10.15430/JCP.2021.26.1.71","DOIUrl":null,"url":null,"abstract":"<p><p>The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"26 1","pages":"71-82"},"PeriodicalIF":2.5000,"publicationDate":"2021-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020174/pdf/","citationCount":"0","resultStr":"{\"title\":\"Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting.\",\"authors\":\"Mark Steven Miller, Peter J Allen, Powel H Brown, Andrew T Chan, Margie L Clapper, Roderick H Dashwood, Shadmehr Demehri, Mary L Disis, Raymond N DuBois, Robert J Glynn, Thomas W Kensler, Seema A Khan, Bryon D Johnson, Karen T Liby, Steven M Lipkin, Susan R Mallery, Emmanuelle J Meuillet, Richard B S Roden, Robert E Schoen, Zelton D Sharp, Haval Shirwan, Jill M Siegfried, Chinthalapally V Rao, Ming You, Eduardo Vilar, Eva Szabo, Altaf Mohammed\",\"doi\":\"10.15430/JCP.2021.26.1.71\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.</p>\",\"PeriodicalId\":15120,\"journal\":{\"name\":\"Journal of Cancer Prevention\",\"volume\":\"26 1\",\"pages\":\"71-82\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2021-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020174/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Prevention\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15430/JCP.2021.26.1.71\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15430/JCP.2021.26.1.71","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting.
The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
